Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Cherlene Hardy
Observed name:
Cherlene Y. Hardy
Institution:
University of Alabama at Birmingham
Observed institution:
University of Alabama at Birmingham
ORCID:
0000-0001-7082-7925
Observed ORCID:
0000-0001-7082-7925
OpenAlex ID:
A5049955202
PAICS, a Purine Nucleotide Metabolic Enzyme, is Involved in Tumor Growth and the Metastasis of Colorectal Cancer
2020
·
Sumit Agarwal
, Balabhadrapatruni V. S. K. Chakravarthi
, et al.
·
Cancers
·
61
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer
2024
·
Jeremy B. Foote
, Tyler E. Mattox
, et al.
·
Cancer Research
·
37
PDF
Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma
2017
·
Jerome T. Higgs
, Joo Hyoung Lee
, et al.
·
Blood Advances
·
14
PDF
Evaluation of a novel Pan-RAS/β-Catenin inhibitor, ADT-030, for treatment of pancreatic cancer.
2024
·
Gary A Piazza
, Reddy DS Bandi
, et al.
·
Journal of Clinical Oncology
·
2
A potent and selective pan-RAS inhibitor, ADT-1004, targeting complex KRAS mutations for pancreatic cancer.
2024
·
Gary A. Piazza
, Reddy D. S. Bandi
, et al.
·
Journal of Clinical Oncology
·
2
PDF
Variable efficacy of the non-covalent KRASG12D inhibitor (MRTX-1133) with obesity in murine pancreatic cancer
2026
·
Sujith Sarvesh
, Holly Stephens
, et al.
·
npj Precision Oncology
PDF
Antibody subclass deficiency accelerates tumorigenesis in genetically engineered mouse models of pancreatic cancer
2026
·
Jeremy B. Foote
, Sujith Sarvesh
, et al.
·
JCI Insight
PDF
Abstract LB080: Obesity contributes to varied efficacy of non-covalent KRASG12Dinhibitor in murine models of pancreatic ductal adenocarcinoma
2026
·
Sujith Sarvesh
, Holly R. Stephens
, et al.
·
Cancer Research
Show more works
View as search
Works count:
8
Citation count:
116
H-index:
3
I10-index:
3
Year
Topic
Type